Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Tables

Table 3. Recommended Doses of First-Line Drugs for Treatment of Tuberculosis in Adults and Adolescents

Last Updated: May 18, 2017; Last Reviewed: May 18, 2017

Table 3. Recommended Doses of First-Line Drugs for Treatment of Tuberculosis in Adults and Adolescents
Drug Daily
Isoniazid 5 mg/kg (usual dose 300 mg)
Rifampina
Note: Rifampin is not recommended in patients receiving HIV PIs, ETR, RPV,
EVG/COBI or TAF
10 mg/kg (usual dose 600 mg)
Rifabutina
without HIV PIs, EFV, RPV
5 mg/kg (usual dose 300 mg)
with HIV PIs 150 mgb
with EFV 450–600 mg
withTAF or EVG/COBI containing regimens not recommended
Pyrazinamide
(weight-based dosing)
40–55 kg
1000 mg (18.2–25.0 mg/kg)

56–75 kg 1500 mg (20.0–26.8 mg/kg)
76-90 kg 2000 mg (22.2–26.3 mg/kg)
>90 kg 2000 mgc
Ethambutol

40–55 kg
800 mg (14.5–20.0 mg/kg)

56–75 kg 1200 mg (16.0–21.4 mg/kg)
76-90 kg 1600 mg (17.8–21.1 mg/kg)
>90 kg 1600 mgc

a For more detailed guidelines on use of different antiretroviral drugs with rifamycin, clinicians should refer to the Drug Interactions section of the Adult and Adolescent ARV Guidelines
b Acquired rifamycin resistance has been reported in patients with inadequate rifabutin levels while on 150 mg twice weekly dosing together with ritonavir-boosted PIs. May consider therapeutic drug monitoring when rifabutin is used with a ritonavir-boosted PI and adjust dose accordingly.
c Monitor for therapeutic response and consider therapeutic drug monitoring to assure dosage adequacy in patients who weigh >90 kg.

Key to Acronyms: COBI = cobicistat; EFV = efavirenz; EVG = elvitegravir; FTC = emtricitabine; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; TAF = tenofovir alafenamide

Download Guidelines